Drug Profile
Research programme: CNS disorder therapies - Neurosciences Victoria/Xuzhou Nhwa Pharmaceutical
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Neurosciences Victoria
- Developer Jiangsu Nhwa Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in Australia
- 16 Jul 2016 No recent reports of development identified for preclinical development in CNS-disorders in China